Multiple Technology Appraisal

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35) [ID783]

Committee papers

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

MULTIPLE TECHNOLOGY APPRAISAL

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35) [ID783]

1 Pre-meeting briefing

2 Assessment Report prepared by Southampton Health Technology Assessments Centre

- Assessment Report
- Erratum

3 Consultee and commentator comments on the Assessment Report from:

- AbbVie
- Bristol Myers Squibb
- Pfizer
- Roche
- British Society for Rheumatology
  The Department of Health informed us they had no comments on this report

4 Response to consultee and commentator comments on the redacted Assessment Report from Southampton Health Technology Assessments Centre

5 Company submissions from:

- AbbVie
- Bristol Myers Squibb
- Pfizer
- Roche

6 Patient groups, professional group and NHS organisation submissions from:

- National Rheumatoid Arthritis Society
- British Society for Paediatric and Adolescent Rheumatology
- Royal College of Pathologists

7 Expert Personal perspectives from:

- Dr Hana Alachkar– clinical expert, nominated by the Royal College of Pathologists
- Dr Kate Armon – clinical expert, nominated by the British Society for Paediatric and Adolescent Rheumatology
- Helen Berger – patient expert, nominated by National Rheumatoid Arthritis Society
- Ailsa Bosworth – patient expert, nominated by the National Rheumatoid Arthritis Society